Alternate Title
Basic Trial Information
Objectives
Entry Criteria
Expected Enrollment
Outline
Published Results
Trial Contact Information
Registry Information

Alternate Title

Positron Emission Tomography in Detecting Testicle Cancer

Basic Trial Information

Phase	Type	Status	Age	Sponsor	Protocol IDs
No phase specified	Diagnostic	Closed	Any age	Other	MRC-TE22 EU-20115, NCT00045045

Objectives

1. Assess the ability of fludeoxyglucose F 18 positron emission tomography to predict relapse requiring adjuvant chemotherapy in patients with high-risk stage I non-seminomatous or mixed seminoma/non-seminomatous germ cell tumor of the testis who are on current management protocols.

Entry Criteria

Disease Characteristics:

• Histologically confirmed non-seminomatous or mixed seminoma/non-seminomatous germ cell tumor of the testis with evidence of vascular (lymphatic or venous) invasion in primary specimen



• Clinical stage I on the basis of clinical examination, chest x-ray, and CT scan of the chest, abdomen, and pelvis



• Negative post-orchidectomy tumor markers (alpha-fetoprotein and beta human chorionic gonadotropin)



• High-risk disease

Prior/Concurrent Therapy:

Biologic therapy

• Not specified

Chemotherapy

• Not specified

Endocrine therapy

• Not specified

Radiotherapy

• Not specified

Surgery

• See Disease Characteristics
• No more than 8 weeks since prior orchidectomy

Other

• No prior positron emission tomography scans

Patient Characteristics:

Age

• Any age

Performance status

• Not specified

Life expectancy

• Not specified

Hematopoietic

• Not specified

Hepatic

• Not specified

Renal

• Not specified

Other

• No evidence of active inflammatory or infective diseases
• No other disease or prior malignancy that would preclude study

Expected Enrollment

Approximately 135 patients will be accrued for this study within 2-3 years.

Outline

This is a multicenter study.

Patients receive fludeoxyglucose F 18 (FDG) IV followed 1 hour later by positron emission tomography (PET) imaging. Patients with metastatic disease identified by FDG PET imaging may receive adjuvant chemotherapy according to the standard clinical practice at each participating center. Patients with no metastatic disease identified by FDG PET imaging are considered for entry into the MRC-TE08 trial (randomized trial of 2 CT scan frequencies in the surveillance of stage I teratoma) or are followed according to the standard surveillance schedule.

Patients with metastatic disease are followed every 6 months. Patients with no metastatic disease are followed monthly for 1 year, every 2 months for 1 year, every 3 months for 1 year, and then every 4-6 months thereafter.

Peer Reviewed and Funded or Endorsed by Cancer Research UK

Huddart RA, O'Doherty MJ, Padhani A, et al.: 18fluorodeoxyglucose positron emission tomography in the prediction of relapse in patients with high-risk, clinical stage I nonseminomatous germ cell tumors: preliminary report of MRC Trial TE22--the NCRI Testis Tumour Clinical Study Group. J Clin Oncol 25 (21): 3090-5, 2007.[PUBMED Abstract]

Trial Contact Information

Trial Lead Organizations

Institute of Cancer Research - London

Robert Huddart, MD, Protocol chair		Ph: 44-20-8661-3457 Email: robert.huddart@icr.ac.uk

Registry Information
Official Title		A Study Of 18 FDG PET In The Prediction Of Relapse In Patients With A Clinical Stage I Non-Seminomatous Germ Cell Tumor
Trial Start Date		2002-05-27
Registered in ClinicalTrials.gov		NCT00045045
Date Submitted to PDQ		2002-06-19
Information Last Verified		2002-09-30

Back to Top